Branched Oyster Mushroom

Metadata

Regulatory Status

Japan

• Status: P. cornucopiae is commercially cultivated and widely sold in Japan under the name Tamogitake. It is classified as an edible mushroom with no specific medicinal claims authorized. Tamogitake is particularly popular in the Nagano and Niigata prefectures of Japan.
• Culinary tradition: Valued in Japanese cuisine for its delicate texture and mild, slightly sweet flavor. Used in miso soup, nabemono (hot pot), tempura, and as a garnish. The mushroom has a characteristic pale yellow to cream coloring and a branched, trumpet-shaped growth pattern.
• Research context: Japanese researchers have conducted the majority of pharmacological studies on P. cornucopiae, including the pivotal double-blind clinical trial on Th1 immune enhancement.

China

• Status: Cultivated commercially and consumed as an edible mushroom. Chinese researchers have contributed studies on polysaccharide pharmacology and macrophage activation.
• Not pharmacopoeial: Not listed in the Chinese Pharmacopoeia.

United States

• Status: Available through specialty mushroom cultivators and some Asian grocery stores. No FDA GRAS determination. Not commonly marketed as a dietary supplement.

European Union

• Status: Consumed as an edible mushroom. No novel food authorization for extracts or supplements. Available through specialty cultivation. Sometimes confused with the closely related Pleurotus citrinopileatus (Golden Oyster), though they are distinct species.

Conditions & Indications

Primary Indications (Clinical and Strong Preclinical Evidence)

• Th1-type immune enhancement — A double-blind, placebo-controlled clinical trial (Tanaka et al., 2016) demonstrated that oral administration of P. cornucopiae (Tamogitake) extract for 8 weeks significantly elevated serum interferon-gamma (IFN-gamma, P = 0.013) and interleukin-12 (IL-12) in human subjects, while Th2 cytokines (IL-4, IL-5, IL-10, IL-13) were minimally changed. This Th1-selective potentiation operates through the macrophage-IL-12-IFN-gamma pathway and represents one of the few mushroom immunomodulatory effects validated in a rigorous human trial.
• Antihypertensive activity — D-mannitol, a major sugar alcohol phytochemical in P. cornucopiae, directly inhibits angiotensin I-converting enzyme (ACE) activity. Oral administration of D-mannitol and hot water extract of Tamogitake lowered blood pressure in spontaneously hypertensive rats (SHR). Additionally, two ACE-inhibitory peptides isolated from P. cornucopiae fruiting bodies demonstrated antihypertensive effects in SHR at 600 mg/kg body weight.

Secondary Indications (Preclinical Evidence)

• Antigenotoxic and DNA-protective activity — P. cornucopiae was identified as the most efficient bio-antimutagenic and antigenotoxic species when tested alongside 89 different mushroom species against Salmonella typhimurium TA98 mutagenesis induced by benzo[a]pyrene. P. cornucopiae extracts also significantly reduced H2O2-induced oxidative DNA damage in V79 Chinese hamster lung cells. This exceptional antigenotoxic potency is a distinguishing feature of the species.
• Proinflammatory macrophage activation — Beta-glucan from P. cornucopiae induced significant increases in TNF-alpha and IL-1-beta mRNA expression in mouse peritoneal macrophages, demonstrating direct innate immune stimulation. This macrophage activation contributes to the Th1 polarization observed in the clinical trial.
• Hypocholesterolemic potential — P. cornucopiae contains lovastatin, a natural HMG-CoA reductase inhibitor, and ergothioneine, an amino acid antioxidant with anti-atherogenic properties. Lovastatin content has been quantified in P. cornucopiae fruiting bodies, contributing to the species’ cardiovascular-protective profile.

Emerging/Preclinical Indications

• Alpha-glucosidase inhibition — P. cornucopiae demonstrated alpha-glucosidase inhibitory activity, suggesting potential for blood glucose management through delayed carbohydrate digestion. This was the first report of alpha-glucosidase inhibitory activity in this species.
• Antioxidant activity — Phenolic compounds in P. cornucopiae contribute to free radical scavenging, and intracellular zinc polysaccharides (IZPS) from the species exhibit notable antioxidant activities both in vitro and in vivo.
• Anticancer potential — Clinical observations in cervical and gastric cancer patients (stage II or III) receiving P. cornucopiae extract showed a reduction in tumor size, though these reports require confirmation in controlled clinical trials.

Mechanism of Action

Primary Mechanisms

1. Th1-selective immune polarization via macrophage-IL-12-IFN-gamma pathway P. cornucopiae polysaccharides activate macrophages to produce interleukin-12 (IL-12), a key cytokine that drives differentiation of naive T helper cells toward the Th1 phenotype. Th1 cells produce interferon-gamma (IFN-gamma), which in turn activates macrophages, NK cells, and cytotoxic T lymphocytes, creating a positive feedback loop that enhances cell-mediated immunity. The clinical trial demonstrated selective elevation of IFN-gamma and IL-12 without significant changes in Th2 cytokines (IL-4, IL-5, IL-10, IL-13), indicating specific Th1 polarization rather than generalized immune activation. This selectivity is therapeutically significant because Th1 responses are critical for antiviral and antitumor immunity, while excessive Th2 activation can promote allergic responses.

2. ACE inhibition by D-mannitol D-mannitol, the primary sugar alcohol in P. cornucopiae, directly inhibits angiotensin I-converting enzyme (ACE), which catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. By inhibiting ACE, D-mannitol reduces angiotensin II production, leading to vasodilation and decreased blood pressure. Among sugar alcohols and sugars tested, D-mannitol showed the strongest ACE inhibitory activity, followed by monosaccharides (D-glucose, D-galactose, D-mannose), with disaccharides showing the lowest potency. Additionally, two specific ACE-inhibitory peptides isolated from the fruiting body provide a complementary antihypertensive mechanism via direct peptide-mediated enzyme inhibition.

3. Antigenotoxic defense through multiple pathways P. cornucopiae’s exceptional antigenotoxic activity against benzo[a]pyrene-induced mutagenesis and H2O2-induced oxidative DNA damage operates through multiple mechanisms: direct scavenging of reactive oxygen species (ROS) that cause oxidative DNA lesions, inhibition of metabolic activation of promutagens (desmutagens), and enhancement of DNA repair processes (bio-antimutagenesis). The species’ superiority over 88 other mushroom species in these assays suggests a uniquely potent combination of these protective mechanisms.

Secondary Mechanisms

• Beta-glucan-mediated proinflammatory macrophage activation: Beta-glucan from P. cornucopiae directly activates peritoneal macrophages, increasing TNF-alpha and IL-1-beta expression. These proinflammatory cytokines enhance innate immune surveillance and contribute to the Th1 polarization observed clinically.
• HMG-CoA reductase inhibition by lovastatin: Naturally occurring lovastatin in P. cornucopiae inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. This mechanism is the same as that of pharmaceutical statins.
• Ergothioneine antioxidant protection: Ergothioneine is a unique thiol amino acid that accumulates in tissues subject to high oxidative stress (erythrocytes, liver, kidney, lens). It acts as an intracellular antioxidant and cytoprotectant, and has been designated a “longevity vitamin” by some researchers.

Key Active Compounds

Clinical Evidence Summary

P. cornucopiae has stronger clinical evidence than most lesser-known Pleurotus species, with a pivotal double-blind clinical trial and multiple well-designed preclinical studies.

Human Clinical Trials

Key Preclinical Studies

Evidence Limitations

• Only one double-blind, placebo-controlled human clinical trial has been conducted, and specific sample size details are limited.
• The antihypertensive effects of D-mannitol and ACE-inhibitory peptides have not been confirmed in human hypertension trials.
• Anticancer observations in cervical and gastric cancer patients lack the rigor of controlled clinical trials and should be considered preliminary.
• The antigenotoxic superiority documented in the 89-species screen has not been confirmed in human biomarker studies.
• Dose-response relationships for human therapeutic use have not been established.
• Limited pharmacokinetic data exist for the bioactive compounds.
• Most preclinical studies were conducted by Japanese research groups, and independent replication by other groups would strengthen the evidence base.

Safety Profile

General Assessment

P. cornucopiae has been consumed as a food mushroom in Japan and East Asia for generations and is commercially cultivated. No adverse effects from dietary consumption have been reported. The double-blind clinical trial (Tanaka et al., 2016) did not report any significant adverse events from 8 weeks of extract supplementation. The mushroom’s long history of culinary use supports a favorable safety profile at food-level doses.

Contraindications

• Known mushroom allergy: Individuals with documented allergies to Pleurotus species or other basidiomycete mushrooms should avoid P. cornucopiae.
• Pregnancy and lactation: Culinary consumption is likely safe based on traditional use. Concentrated extract supplementation should be avoided due to insufficient specific safety data.

Drug Interactions

• Potential — antihypertensives and ACE inhibitors: Given demonstrated ACE-inhibitory activity through both D-mannitol and peptide compounds, concurrent use of concentrated P. cornucopiae extracts with prescribed antihypertensive medications (particularly ACE inhibitors like enalapril, lisinopril) could theoretically produce additive blood pressure-lowering effects. Monitor blood pressure if combining. Severity: Low-to-moderate (theoretical).
• Potential — statins: Lovastatin content means concurrent use with prescribed statin medications could theoretically increase statin-related side effects (myopathy). The lovastatin content in food-level consumption is likely too low to be clinically significant, but concentrated extracts warrant caution.
• Potential — immunosuppressants: The Th1-enhancing immune effects documented in the clinical trial suggest potential interference with immunosuppressive therapy. Patients on immunosuppressive regimens should exercise caution.
• Potential — anticoagulants: No specific anticoagulant interactions documented, but general caution is warranted.

Side Effects

• From food consumption: No adverse effects documented from culinary use.
• From extract supplementation: No significant adverse events reported in the 8-week clinical trial.
• General: Mild gastrointestinal discomfort possible with high-dose polysaccharide supplementation.

Clinical Dosage

As Culinary Food

• Fresh fruiting body: No specific therapeutic dose established. Consumed as a culinary ingredient in Japanese cuisine. The mushroom’s branched, trumpet-shaped clusters have a delicate, slightly sweet flavor suitable for soups, stir-fries, and tempura.
• Typical culinary serving: 50-100 g fresh weight per serving, consistent with other Pleurotus species.

Based on Clinical Trial

• Tamogitake extract (immune enhancement): The Tanaka et al. (2016) trial used Tamogitake extract administered orally for 8 weeks to achieve Th1 immune enhancement. Specific dosing details should be referenced from the original publication.

Extrapolated from Animal Studies (No Full Human Validation)

• ACE inhibitory peptides: 600 mg/kg body weight in SHR for antihypertensive effect; human-equivalent dose not formally established.
• D-mannitol: Active as ACE inhibitor in vitro and in vivo in rats; optimal human therapeutic dose not determined.

Preparation Notes

• The fruiting body is the only part used both culinarily and medicinally.
• Hot water extraction is standard for isolating polysaccharides and is the basis for the extract used in the clinical trial.
• The mushroom should be cooked before consumption, as with all Pleurotus species.

Sources

• Tanaka A, Nishimura M, Sato Y, et al. Enhancement of the Th1-phenotype immune system by the intake of Oyster mushroom (Tamogitake) extract in a double-blind, placebo-controlled study. J Tradit Complement Med. 2016;6(4):424-430
• Hagiwara SY, Takahashi M, Shen Y, et al. A phytochemical in the edible Tamogi-take mushroom (Pleurotus cornucopiae), D-mannitol, inhibits ACE activity and lowers the blood pressure of spontaneously hypertensive rats. Biosci Biotechnol Biochem. 2005;69(8):1603-1605
• Mlinaric A, Kac J, Pohleven F. Antigenotoxic activity of the mushroom Pleurotus cornucopiae against chemical and UV-induced mutagenesis. Mutagenesis. 2004;19(6):453-457
• de Oliveira TM, et al. A Proinflammatory Effect of the Beta-Glucan from Pleurotus cornucopiae Mushroom on Macrophage Action. Mediators Inflamm. 2017;2017:8402405
• Miyauchi M, et al. Novel angiotensin I-converting enzyme inhibitory peptides derived from an edible mushroom, Pleurotus cornucopiae. Peptides. 2009;30(5):884-891
• Reis FS, et al. Effect of different substrates on Pleurotus spp. cultivation in Brazil - Ergothioneine and lovastatin. J Food Compos Anal. 2022;106:104340
• Palmieri B, et al. Promising anticancer activity of polysaccharides and other macromolecules derived from oyster mushroom (Pleurotus sp.): An updated review. Int J Biol Macromol. 2021;183:2196-2208
• Japanese Patent JP2005068114A. Pleurotus cornucopiae fruit body composition, method for producing the same, and immunopotentiator, anticancer agent and food product. Filed 2003
• Khan MA, Tania M. Nutritional and medicinal importance of Pleurotus mushrooms: an overview. Food Rev Int. 2012;28(3):313-329
• Jayachandran M, Xiao J, Xu B. A critical review on health promoting benefits of edible mushrooms through gut microbiota. Int J Mol Sci. 2017;18(9):1934

Connections

• Oyster Mushroom — The common oyster mushroom (P. ostreatus) is the most studied Pleurotus species and provides the baseline pharmacological comparator. P. cornucopiae has a distinct bioactive profile, notably its superior antigenotoxic activity and the specific Th1-polarizing immune effect validated in a human trial.
• King Trumpet — Another culinary-medicinal Pleurotus species. P. eryngii is the most commercially important species for cultivation, while P. cornucopiae’s ACE-inhibitory D-mannitol content distinguishes its cardiovascular profile.
• Golden Oyster — Sometimes confused with P. cornucopiae due to similar coloring, but they are distinct species with different bioactive profiles. P. citrinopileatus has antitumor polysaccharides while P. cornucopiae has the documented Th1 clinical trial and antigenotoxic superiority.
• Pink Oyster — Both P. cornucopiae and P. djamor were first reported to contain ergothioneine in the same analytical study, contributing to the understanding of ergothioneine distribution across the Pleurotus genus.
• Lung Oyster — A Pleurotus species with documented immunomodulatory polysaccharides; useful as a genus-level pharmacological comparator.
• Turkey Tail — The clinical evidence for PSK/PSP in cancer adjunctive therapy provides context for P. cornucopiae’s preliminary anticancer observations. Both species activate innate immune pathways.
• Reishi — Reishi’s well-characterized immune modulation profile provides the benchmark for evaluating P. cornucopiae’s Th1-selective enhancement.
• Maitake — Maitake D-fraction activates dendritic cells and macrophages, complementing P. cornucopiae’s macrophage-IL-12-IFN-gamma pathway for potential multi-mushroom immune support protocols.